Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aurinia Pharmaceuticals Inc AUPH

Aurinia Pharmaceuticals Inc. is a Canada-based fully integrated biopharmaceutical company. The Company is focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. The Company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory activities to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil (MMF) and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. Its product pipeline includes AUR200 and AUR300.


NDAQ:AUPH - Post by User

Bullboard Posts
Comment by highshooteron Mar 14, 2017 12:03pm
208 Views
Post# 25976718

RE:how the stock market works (oldie, but a goodie)

RE:how the stock market works (oldie, but a goodie)loving it. 
Here AUP is even worst.  Aurinia executives don't manage the business to serve the interest of traders and their desire to flip the stock for a few bucks' profit. The company's goal was to bring in significant money to fund the development of voclosporin and to build a roster of new institutional shareholders interested in owning the company for the long term.
Aurinia says




They manipulate the stock with GOOD news then proceed to take advantage of the rise in price for their own benefit ...then blame the investor for not seeing it coming ...cause they are there for the development of VOclosporin.
SURE IT DID NOT SERVE THEIR GOAL . THEY HAD NO IDEA OF WHAT WAS GOING TO HAPPEN .
a roster of new institutional shareholders interested in owning the company for the long term.
Aurinia says
WELL from INSIDER MONKEY No top funds that we track were long Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) at the end of Q4
Had sold my share on the rise and keep following this stock ( have for almost 20 years back then ISOTEKNICA own it ) might still buy into it might not.....Just hoping to save some pain . Trust me I sufferred many time prior to learning the saying SELL ON GREED BUY ON FEAR.
Greed was just a few days back.......

Bullboard Posts